Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;1878(6):189004.
doi: 10.1016/j.bbcan.2023.189004. Epub 2023 Oct 20.

CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways

Affiliations
Free article
Review

CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways

Layla Haymour et al. Biochim Biophys Acta Rev Cancer. 2023 Nov.
Free article

Abstract

Although the interaction of CD95L (also known as FasL) with its so-called death receptor CD95 (Fas) induces an apoptotic signal responsible for the elimination of infected and cancer cells and maintenance of tissue homeostasis, this receptor can also implement non apoptotic signaling pathways. This latter signaling is involved in metastatic dissemination in certain cancers and the severity of auto-immune disorders. The signaling complexity of this pair is increased by the fact that CD95 expression itself seems to contribute to oncogenesis via a CD95L-independent manner and, that both ligand and receptor might interact with other partners modulating their pathophysiological functions. Finally, CD95L itself can trigger cell signaling in immune cells rendering complex the interpretation of mouse models in which CD95 or CD95L are knocked out. Herein, we discuss these non-canonical responses and their biological functions.

Keywords: CD95; Ligand independent signal; NF-κB; Reverse signaling; TNF.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Legembre has patent #WO2015158810 issued to inserm transfert. Legembre has patent #WO2017149012 pending to inserm transfert. Legembre has patent #WO2018130679 issued to inserm transfert. no other conflict of interest.

Publication types